Compare BANF & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANF | MMED |
|---|---|---|
| Founded | 1984 | 1983 |
| Country | United States | United States |
| Employees | 2260 | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.1B |
| IPO Year | N/A | 2026 |
| Metric | BANF | MMED |
|---|---|---|
| Price | $113.83 | $15.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $124.00 | $22.56 |
| AVG Volume (30 Days) | 205.0K | ★ 1.1M |
| Earning Date | 04-16-2026 | 06-03-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.10 | $15.99 |
| Revenue Next Year | $3.92 | $10.00 |
| P/E Ratio | $16.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $101.48 | $10.65 |
| 52 Week High | $138.15 | $17.86 |
| Indicator | BANF | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 54.08 | 64.57 |
| Support Level | $110.33 | $10.68 |
| Resistance Level | $115.82 | $15.74 |
| Average True Range (ATR) | 2.84 | 0.87 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 55.03 | 91.63 |
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Its Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.